Improved survival after acute graft-versus-host disease diagnosis in the modern era
暂无分享,去创建一个
Alan M. Miller | R. Vij | W. Wood | M. Aljurf | R. Gale | J. Pidala | H. Khoury | Yi-Bin Chen | R. Martino | S. Spellman | Tao Wang | M. Cairo | M. Ayas | Michael T. Hemmer | M. Arora | D. Couriel | A. Alousi | M. Qayed | G. Socié | C. Dandoy | L. Verdonck | P. Hematti | J. Storek | S. Hashmi | M. Litzow | C. Cutler | L. Lehmann | K. Schultz | N. Majhail | B. Wirk | M. Battiwalla | U. Gergis | R. Kamble | B. Savani | H. Schoemans | M. Jagasia | J. Antin | J. Cahn | M. Kharfan-Dabaja | R. Hayashi | H. Schouten | T. Nishihori | M. Juckett | M. Carabasi | Lolie C. Yu | K. Jamani | M. Solh | A. Miller
[1] S. Nikiforow,et al. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] M. Robin,et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] P. Westervelt,et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. , 2014, Blood.
[4] S. Grupp,et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. , 2014, Blood.
[5] Stephanie J. Lee,et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. MacMillan,et al. What predicts high risk acute graft‐versus‐host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score , 2012, British journal of haematology.
[7] J. Bolaños-Meade,et al. Graft-versus-host disease treatment: predictors of survival. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] Michael Boeckh,et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.
[9] J. Pidala,et al. Glucocorticoid-refractory acute graft-versus-host disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] M. Pasquini,et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. , 2009, Blood.
[11] J. Klein,et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] J. Fay,et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. , 2000, Blood.
[13] A. Nademanee,et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. , 1998, Blood.
[14] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[15] K. Sullivan,et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.